3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 2/3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
13
Carcinoma, Non-Small-Cell Lung
11
Neoplasm Metastasis
7
Brain Neoplasms
7
Rectal Neoplasms
6
Lung Neoplasms
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Prostatic Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Pancreatic Neoplasms
3
Melanoma
3
Glioblastoma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Laryngeal Neoplasms
2
Inflammatory Breast Neoplasms
2
Glioma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Adenocarcinoma
2
Vaginal Neoplasms
1
Interventions
Carboplatin
17
Cisplatin
14
Paclitaxel
12
Pemetrexed
11
pembrolizumab
9
Gemcitabine
7
Docetaxel
6
Sorafenib
5
osimertinib
4
durvalumab
4
130-nm albumin-bound paclitaxel
4
padeliporfin
3
cabozantinib
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Cetuximab
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
Surgical Procedures, Operative
×
Clear all
NCT03800134
2025-06-11
AEGEAN
AstraZeneca
Phase 3
Active not recruiting
825 enrolled
1 FDA